AstraZeneca Atacand comparative efficacy
Executive Summary
FDA's Cardiovascular & Renal Drugs Advisory Committee will review Atacand (candesartan) for proposed comparative efficacy claim to Merck's Cozaar (losartan) in treatment of hypertension on July 18. The sNDA (20-338/S-015) is based on AstraZeneca's CLAIM studies conducted in 1,200 patients. The meeting will take place at the Holiday Inn-Bethesda, Md., beginning at 8 a.m. [To sign up for a 1webcast, go to FDAAdvisoryCommittee.com]....You may also be interested in...
The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
Gene Therapy Approvals By US FDA Could Double In 2020
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: